LifeStance shares surge after profitable quarter, $100M buyback
Mental health provider turns profitable, exceeds revenue estimates and initiates share repurchase
LifeStance Health Group shares jumped 3.8% on Wednesday after the mental health services provider reported better-than-expected quarterly revenue, swung to profitability, and announced a $100 million share repurchase program.
The company reported fourth-quarter revenue of $382.2 million, a 17% increase from a year earlier and exceeding analyst estimates by 7.7%, according to GlobeNewswire. LifeStance achieved its first full year of net profitability in 2025, with GAAP earnings per share of $0.03 for the quarter.
The performance marked a significant turnaround from the prior year, when the company posted a $7.1 million net loss in the same quarter. Adjusted EBITDA surged 49% to $48.8 million, representing a 12.8% margin and underscoring operational efficiency gains across the business.
LifeStance's clinician network expanded to 8,040 providers, up 9% year-over-year, supporting its growth in the rapidly expanding telehealth market. The global telehealth sector is projected to reach $191.88 billion in 2026, growing at a compound annual growth rate of 24.7% through 2035, according to market research.
"This momentum reflects our clinicians' continued dedication to delivering high-quality care and our ability to scale our operations efficiently," the company said in its earnings release. "We are confident in our ability to sustain growth while driving profitability."
The board's authorization of a $100 million share repurchase program signaled management's confidence in the company's financial position and future prospects. The buyback initiative represents approximately 3.6% of LifeStance's $2.78 billion market capitalization based on Tuesday's closing price.
For 2026, LifeStance provided guidance projecting revenue between $1.615 billion and $1.655 billion, with Adjusted EBITDA expected to reach $185 million to $205 million. The outlook suggests continued revenue growth of 18% to 21% compared to 2025 levels.
Analysts have responded positively to the results. Of the 10 analysts covering the stock, nine rate it a buy or strong buy with an average target price of $9.00, according to market data. The stock remains below its 52-week high of $8.29 but has recovered significantly from its 52-week low of $3.74.
Institutional investors own 96.7% of outstanding shares, reflecting strong institutional confidence in the company's business model despite earlier concerns about profitability in the digital health sector.
LifeStance's turnaround coincides with broader consolidation in the mental health services market, where companies have faced pressure to demonstrate sustainable unit economics after the pandemic-driven surge in telehealth adoption. The company's ability to achieve profitability while maintaining double-digit revenue growth positions it favorably against competitors still struggling with margin expansion.
The stock's 3.8% gain in Wednesday trading follows a more dramatic pre-market surge of 10.6% and an initial post-earnings jump of 12.7%, according to TradingView data. The more tempered intraday performance suggests investors are weighing the strong quarterly results against broader market volatility.
LifeStance, headquartered in Scottsdale, Arizona, provides outpatient mental health services to children, adolescents, adults and geriatrics through its network of clinicians across the United States. The company went public in 2021 during the height of telehealth enthusiasm but has faced pressure to demonstrate sustainable profitability.
The $100 million buyback authorization represents a significant capital allocation shift for a company that had previously focused resources on expansion and clinician recruitment. The move suggests management believes the stock remains undervalued despite its recent recovery from 52-week lows.